Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

Locally advanced prostate cancer treated with radiotherapy and androgen deprivation

Nature Clinical Practice Urology volume 2, pages 304–308 (2005)Cite this article

Abstract

Background A 60-year-old man, with a 2-year history of lower-urinary-tract symptoms (frequency and reduced flow) and perineal discomfort, presented with a serum PSA level of 42 ng/ml.

Investigations Digital rectal examination, transrectal ultrasound, prostate biopsy (8 cores), prostate and pelvic MRI, renal ultrasound and bone scan.

Diagnosis cT3b, N0, M0 prostate cancer (Gleason score 7 [4 + 3]).

Management Hormonal down-staging with bicalutamide 150 mg/day for 3 months, then conformal radiotherapy (70 Gy over 7 weeks) with adjuvant bicalutamide 150 mg/day, to be continued until disease progression. Breast radiotherapy administered over a 5-day period at a dose of 15 Gy to reduce nonsteroidal antiandrogen-associated gynecomastia and breast pain.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Aus G et al. (online 2004) European Association of Urology guidelines on prostate cancer. [http://www.uroweb.org/files/uploaded_files/prostatecancer.pdf] (accessed 18 May 2005).

  2. The Medical Research Council Prostate Cancer Working Party (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 79: 235–246

  3. Iversen P et al. (2000) Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 164: 1579–1582

    Article  CAS  Google Scholar 

  4. Wirth MP et al. (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172 (Pt 1): 1865–1870

    Article  CAS  Google Scholar 

  5. Chuba PJ et al. (2001) The 1989 patterns of care study for prostate cancer: five-year outcomes. Int J Radiat Oncol Biol Phys 50: 325–334

    Article  CAS  Google Scholar 

  6. Vicini FA et al. (2002) An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 95: 2126–2135

    Article  Google Scholar 

  7. Roach M et al. (2000) Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47: 609–615

    Article  CAS  Google Scholar 

  8. Pollack A et al. (2000) External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 48: 507–512

    Article  CAS  Google Scholar 

  9. Hanks GE et al. (1999) Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am 5: 152–158

    CAS  PubMed  Google Scholar 

  10. Pilepich MV et al. (2001) Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50: 1243–1252

    Article  CAS  Google Scholar 

  11. Laverdière J et al. (2004) The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 171: 1137–1140

    Article  Google Scholar 

  12. Hanks GE et al. (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21: 3972–3978

    Article  CAS  Google Scholar 

  13. Pilepich MV et al. (2005) Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate—long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61: 1285–1290

    Article  CAS  Google Scholar 

  14. Bolla M et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103–106

    Article  CAS  Google Scholar 

  15. Sieber PR et al. (2004) Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 171 (Pt 1): 2272–2276

    Article  CAS  Google Scholar 

  16. Boccardo F et al. (2003) Tamoxifen (T) is more effective than anastrozole (A) in preventing gynecomastia induced by bicalutamide (B) monotherapy in prostate cancer (pca) patients (pts) [abstract 1608]. Proc Am Soc Clin Oncol 22: 400

    Google Scholar 

  17. Tyrrell CJ et al. (2004) Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 60: 476–483

    Article  Google Scholar 

Download references

Acknowledgements

Written permission to publish this case was obtained from the patient concerned. Editorial support was provided by Sarah Goodger, PhD; financial assistance for this support was provided by AstraZeneca.

Author information

Authors and Affiliations

  1. Visiting Professor in the Department of Urology at St George's Hospital, London, UK

    Roger Kirby

Authors
  1. Roger Kirby
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger Kirby.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirby, R. Locally advanced prostate cancer treated with radiotherapy and androgen deprivation. Nat Rev Urol 2, 304–308 (2005). https://doi.org/10.1038/ncpuro0212

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0212

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing